PROACT 3: Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
Massachusetts General Hospital
Summary
The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.
Description
The PROACT 3 clinical trial is designed to evaluate whether disclosure of a polygenic risk score for CAD PRS influences cardiovascular health and risk factor modification over one year. This is a single-center, randomized clinical trial conducted within the Mass General Brigham primary care network. Adults aged 30-75 years without cardiovascular disease and not currently taking LDL cholesterol-lowering medications will be identified through electronic health record queries. A total of 500 participants will be enrolled. All participants will undergo CAD PRS testing. Participants will then be…
Eligibility
- Age range
- 30–75 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Current age 30-75 years * Established primary care at Mass General Brigham with at least one visit in the last 2 years Exclusion Criteria: \- Currently taking LDL cholesterol- lowering medications, including statins
Interventions
- BehavioralImmediate disclosure of CAD PRS results
Participants receive their CAD PRS results as soon as they are available after genotyping.
- BehavioralDeferred Disclosure of CAD PRS results
Participants receive their CAD PRS results after completion of the 12 month follow up period.
Location
- Massachusetts General HospitalBoston, Massachusetts